Responses to commentary on 'Efficacy and safety of neoadjuvant immunotherapy in surgically resectable esophageal cancer: a systematic review and meta-analysis' ( Int J Surg 2022 ;106:106929)

Int J Surg. 2023 Jun 1;109(6):1825-1834. doi: 10.1097/JS9.0000000000000262.

Authors

Zhaoyang Wang¹, Yuanyong Wang¹, Yingtong Feng², Xiaolong Yan¹

Affiliations

¹ Department of Thoracic Surgery, Tangdu Hospital, The Air Force Military Medical University, Xi'an.
² Department of Cardiothoracic Surgery, the Affiliated Huaihai Hospital of Xuzhou Medical University / the 71th Group Army Hospital of PLA, Xuzhou, China.

No abstract available

Publication types

Meta-Analysis
Systematic Review

MeSH terms

Esophageal Neoplasms* / surgery
Humans
Neoadjuvant Therapy*